Yoshikane Kikushige

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 10

Top Topics

Chronic Lymphocytic Leukemia

Multiple Myeloma

Top Venues

Expert review of clinical immunology

International journal of hematology

This page only lists publications with an associated author ORCID identifier.

Publications

Yasuo Mori, Jun Takizawa, Yuna Katsuoka, Naoki Takezako, Koji Nagafuji, Hiroshi Handa, Junya Kuroda, Kazutaka Sunami, Tomohiko Kamimura, Ryosuke Ogawa, Yoshikane Kikushige, Mine Harada, Koichi Akashi, Toshihiro Miyamoto, null null
Autologous HSCT with novel agent-based induction and consolidation followed by lenalidomide maintenance for untreated multiple myeloma. Cancer science 115 (6) (2024)
Yasuo Mori, Jun Takizawa, Yuna Katsuoka, Naoki Takezako, Koji Nagafuji, Hiroshi Handa, Junya Kuroda, Kazutaka Sunami, Tomohiko Kamimura, Ryosuke Ogawa, Yoshikane Kikushige, Mine Harada, Koichi Akashi, Toshihiro Miyamoto, null null
Autologous HSCT with novel agent-based induction and consolidation followed by lenalidomide maintenance for untreated multiple myeloma. Cancer science 115 (6) (2024)
Shinichiro Tsunoda, Takuya Harada, Yoshikane Kikushige, Tadamitsu Kishimoto, Kazuyuki Yoshizaki
Immunology and targeted therapy in Castleman disease. Expert review of clinical immunology 20 (9) (2024)
Shinichiro Tsunoda, Takuya Harada, Yoshikane Kikushige, Tadamitsu Kishimoto, Kazuyuki Yoshizaki
Immunology and targeted therapy in Castleman disease. Expert review of clinical immunology (2024)
Yasuo Mori, Jun Takizawa, Yuna Katsuoka, Naoki Takezako, Koji Nagafuji, Hiroshi Handa, Junya Kuroda, Kazutaka Sunami, Tomohiko Kamimura, Ryosuke Ogawa, Yoshikane Kikushige, Mine Harada, Koichi Akashi, Toshihiro Miyamoto, null null
Autologous HSCT with novel agent-based induction and consolidation followed by lenalidomide maintenance for untreated multiple myeloma. Cancer science (2024)
Yasuo Mori, Jun Takizawa, Yuna Katsuoka, Naoki Takezako, Koji Nagafuji, Hiroshi Handa, Junya Kuroda, Kazutaka Sunami, Tomohiko Kamimura, Ryosuke Ogawa, Yoshikane Kikushige, Mine Harada, Koichi Akashi, Toshihiro Miyamoto, null null
Autologous HSCT with novel agent-based induction and consolidation followed by lenalidomide maintenance for untreated multiple myeloma. Cancer science 115 (6) (2024)
Shinichiro Tsunoda, Takuya Harada, Yoshikane Kikushige, Tadamitsu Kishimoto, Kazuyuki Yoshizaki
Immunology and targeted therapy in Castleman disease. Expert review of clinical immunology (2024)
Yasuo Mori, Jun Takizawa, Yuna Katsuoka, Naoki Takezako, Koji Nagafuji, Hiroshi Handa, Junya Kuroda, Kazutaka Sunami, Tomohiko Kamimura, Ryosuke Ogawa, Yoshikane Kikushige, Mine Harada, Koichi Akashi, Toshihiro Miyamoto, null null
Autologous HSCT with novel agent-based induction and consolidation followed by lenalidomide maintenance for untreated multiple myeloma. Cancer science 115 (6) (2024)
Yoshikane Kikushige
TIM-3 in normal and malignant hematopoiesis: Structure, function, and signaling pathways. Cancer science 112 (9) (2021)
Yoshikane Kikushige
Pathophysiology of chronic lymphocytic leukemia and human B1 cell development. International journal of hematology 111 (5) (2019)